Clinical Trials Logo

Clinical Trial Summary

The investigators are studying a new antidepressant medicine, desvenlafaxine, for the treatment of people with chronic depression. Desvenlafaxine (trade name Pristiq) has been approved by the FDA for the treatment of major depression.

The investigators are testing whether this medicine is also effective for adults with a type of chronic depression that is less severe than major depression. This condition is also known as dysthymic disorder or dysthymia. Chronic depression, lasting two or more years, often causes significant suffering and impairment.

In addition, the investigators are using MRI imaging, which uses magnetic signals to make pictures of the brain's structure and also of its functioning. The purpose of MRI imaging in this study is to see whether chronic depression is associated with differences in brain structure or functioning, and whether such differences change after medication or placebo treatment. To test this MRI scans are done at the start of the study and after 12 weeks of medication or placebo treatment. Getting MRI imaging will be an option for participants in this study but is not required.

This study involves a 6 to 12 week double-blind period during which half of the participants will take the new medication and half will take a placebo (an inactive look-alike pill). After the double blind phase, all subjects can be treated for 12 weeks with an FDA-approved antidepressant medication.

Assessments (of depressive symptoms, social functioning, and personality) will be done by study staff and by patients before the study starts, at each study visit for the first 12 weeks, and again after 24 weeks in the study.


Clinical Trial Description

The investigators wish to study acute efficacy for 12 weeks on a double blind basis and continued response after open-label treatment at week 24 follow-up. It is important to establish the acute (12 week) efficacy of desvenlafaxine in non-major chronic depression. Also, given that non-major chronic depression is by definition chronic, it is important to demonstrate that benefit persists at follow-up assessment (24 weeks); this is clinically important in trying to alleviate the significant psychosocial morbidity associated with this disorder.

The investigators believe this study will have significant value in the treatment of patients with non-major chronic depression, and will add significantly to what remains an extremely small scientific literature.

The investigators would also like to study the effects of desvenlafaxine on brain structure and function. Learning that a medication reduces symptoms does not teach us how the medication achieves this outcome. Participants in this study can have the opportunity to participate in MRI scanning that will help to understand the mechanisms by with desvenlafaxine is effective. MRI scans are done prior to starting the clinical trial and then again after completing the double blind clinical trial. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT01537068
Study type Interventional
Source New York State Psychiatric Institute
Contact
Status Completed
Phase Phase 4
Start date February 2012
Completion date December 2016

See also
  Status Clinical Trial Phase
Completed NCT01583400 - Enhanced Collaborative Depression Treatment in Primary Care: The RESPECT-D-E Trial N/A
Recruiting NCT00260390 - Testosterone Replacement in Middle-Aged Hypogonadal Men With Dysthymia: Parallel Group, Double Blind Randomized Trial Phase 4
Completed NCT00518986 - Efficacy and Safety of Armodafinil for Adults With Excessive Sleepiness Obstructive Sleep Apnea/Hypopnea and Depression Phase 4
Completed NCT04437485 - eIMPACT-DM Pilot Trial: Depression Treatment to Reduce Diabetes Risk Phase 2
Completed NCT01892124 - Motivational Interviewing and Cognitive Behavioral Therapy-based Intervention for Cardiovascular Disease Prevention Amongst American Indians With Diabetic and Depressive Symptoms N/A
Active, not recruiting NCT01473615 - Mindfulness Based Cognitive Therapy for Chronic Pain and Comorbid Unipolar Depression N/A
Completed NCT01542957 - Cognitive Therapy for Unipolar Depression: Efficacy of a Dilemma-Focused Intervention N/A
Completed NCT00619411 - Interpersonal Psychotherapy for Depressed Adolescents and Parents Phase 1
Completed NCT00225251 - Wellbutrin XL for Dysthymic Disorder Phase 4
Recruiting NCT03507114 - Rumination Focus Cognitive Behavior Therapy N/A
Recruiting NCT03917550 - RECOVERY: A Transdiagnostic Intervention for Anxiety and Depression N/A
Completed NCT00688818 - Quetiapine in Co-Morbid Depressive and Anxiety Disorders N/A
Completed NCT00220701 - Escitalopram in the Treatment of Dysthymic Disorder, Double Blind Phase 4
Completed NCT00096642 - Cognitive Behavioral Therapy for Early-Onset Depression N/A
Completed NCT02458690 - eIMPACT Trial: Modernized Collaborative Care to Reduce the Excess CVD Risk of Older Depressed Patients Phase 2
Completed NCT00883519 - The Efficacy of Parent Involvement in the Treatment of Adolescent Depression Phase 1/Phase 2
Completed NCT01852383 - Duloxetine Treatment in Elderly With Dysthymia Phase 4
Completed NCT01561105 - Improving Depression Care for Elders: Coordinating Center N/A
Not yet recruiting NCT05118594 - Testing a Precision Psychotherapy System for Low-income Patients N/A
Completed NCT00073359 - Effects of Therapist Behavior on the Treatment of Depressed Adolescents Phase 1/Phase 2